Lucia Del Mastro

Summary

Affiliation: National Cancer Research Institute
Country: Italy

Publications

  1. ncbi Is it possible to use anthracyclines in patients older than 70 years? Contra
    Lucia Del Mastro
    Istituto Nazionale per la Ricerca sul Cancro, Genoa
    Tumori 88:S136-7. 2002
  2. doi Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial
    Lucia Del Mastro
    S S Sviluppo Terapie Innovative, Oncologia Medica A, Istituto Nazionale per la Ricerca sul Cancro, L go R Benzi 10, 16132 Genova, Italy
    JAMA 306:269-76. 2011
  3. pmc Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study
    Matteo Clavarezza
    Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy
    BMC Cancer 12:216. 2012
  4. pmc Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
    Lucia Del Mastro
    IRCCS AOU San Martino IST National Institute for Cancer Research, UO Sviluppo Terapie Innovative, Genoa, Italy
    BMC Cancer 13:164. 2013
  5. doi Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Lucia Del Mastro
    Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martini IST, Largo Rosanna Benzi, 10, 16132, Genova, Italy
    Expert Rev Anticancer Ther 12:1391-405. 2012
  6. ncbi Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
    L Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, 16132 Genoa, Italy
    Ann Oncol 16:253-8. 2005
  7. doi Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives
    Lucia Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, Genoa, Italy
    Cancer Treat Rev 37:208-11. 2011
  8. doi Medical approaches to preservation of fertility in female cancer patients
    Lucia Del Mastro
    SS Sviluppo Terapie Innovative, National Institute for Cancer Research, Genova, Italy
    Expert Opin Pharmacother 12:387-96. 2011
  9. ncbi Infertility and pregnancy after breast cancer: current knowledge and future perspectives
    Lucia Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, 16132 Genova, Italy
    Cancer Treat Rev 32:417-22. 2006
  10. ncbi Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
    L Del Mastro
    Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 17:74-8. 2006

Detail Information

Publications52

  1. ncbi Is it possible to use anthracyclines in patients older than 70 years? Contra
    Lucia Del Mastro
    Istituto Nazionale per la Ricerca sul Cancro, Genoa
    Tumori 88:S136-7. 2002
  2. doi Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial
    Lucia Del Mastro
    S S Sviluppo Terapie Innovative, Oncologia Medica A, Istituto Nazionale per la Ricerca sul Cancro, L go R Benzi 10, 16132 Genova, Italy
    JAMA 306:269-76. 2011
    ..Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available...
  3. pmc Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study
    Matteo Clavarezza
    Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy
    BMC Cancer 12:216. 2012
    ..International treatment guidelines recommend administration of adjuvant chemotherapy in early breast cancer based on clinical, prognostic and predictive parameters...
  4. pmc Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
    Lucia Del Mastro
    IRCCS AOU San Martino IST National Institute for Cancer Research, UO Sviluppo Terapie Innovative, Genoa, Italy
    BMC Cancer 13:164. 2013
    ..This open-label study compared docetaxel/gemcitabine vs. paclitaxel/gemcitabine and a weekly (W) vs. 3-weekly (3 W) schedule in metastatic breast cancer (MBC)...
  5. doi Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Lucia Del Mastro
    Istituto Di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria San Martini IST, Largo Rosanna Benzi, 10, 16132, Genova, Italy
    Expert Rev Anticancer Ther 12:1391-405. 2012
    ..This review is focused on the available results obtained with the use of trastuzumab in the subset of HER2-positive breast cancer patients with metastatic disease...
  6. ncbi Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
    L Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, 16132 Genoa, Italy
    Ann Oncol 16:253-8. 2005
    ..First-line chemotherapy regimens suitable for elderly advanced breast cancer patients are still not defined...
  7. doi Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives
    Lucia Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, Genoa, Italy
    Cancer Treat Rev 37:208-11. 2011
    ....
  8. doi Medical approaches to preservation of fertility in female cancer patients
    Lucia Del Mastro
    SS Sviluppo Terapie Innovative, National Institute for Cancer Research, Genova, Italy
    Expert Opin Pharmacother 12:387-96. 2011
    ..the loss or impairment of ovarian function is an irreversible side effect that can occur in young cancer patients undergoing anticancer treatments. Its incidence varies according to the type of chemotherapy and the patient's age...
  9. ncbi Infertility and pregnancy after breast cancer: current knowledge and future perspectives
    Lucia Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Largo Rosanna Benzi 10, 16132 Genova, Italy
    Cancer Treat Rev 32:417-22. 2006
    ....
  10. ncbi Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
    L Del Mastro
    Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Ann Oncol 17:74-8. 2006
    ..This phase II study aimed to assess the activity of such a method in young, breast cancer patients undergoing adjuvant chemotherapy...
  11. pmc HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
    L Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, Genoa, Italy
    Br J Cancer 93:7-14. 2005
    ..Our data suggest a potential role of HER-2 overexpression in predicting the efficacy of dose-dense epirubicin-containing chemotherapy and the need to confirm this hypothesis in future prospective studies...
  12. ncbi Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group
    L Del Mastro
    Oncologia Medica A, Istituto Nazionale per Ricerca sul Cancro, Largo Rosanna Benzi, Genova, Italy
    Ann Oncol 19:299-307. 2008
    ..We analyzed the outcome of both pre- and postmenopausal women who entered two randomized trials (Gruppo Oncologico Nord-Ovest-Mammella Intergruppo studies) on adjuvant chemotherapy and received either concomitant or sequential TAM...
  13. ncbi Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors
    Lucia Del Mastro
    Department of Medical Oncology, National Cancer Research Institute, L go R Benzi 10, 16132 Genoa, Italy
    Cancer Treat Rev 33:681-7. 2007
    ..Here, we review recent updated results obtained with AIs as adjuvant therapy, in terms of reducing the risk of distant metastases...
  14. ncbi Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma
    Marco Venturini
    Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Cancer 97:1174-80. 2003
    ..The objective of this study was to evaluate the activity and safety of oral capecitabine in combination with docetaxel and epirubicin (TEX) as first-line treatment for patients with locally advanced/metastatic breast carcinoma...
  15. doi Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials
    Lucia Del Mastro
    UO Development of Innovative Therapies, Medical Oncology Department, IRCCS AOU San Martino IST, National Institute for Cancer Research, Genova, Italy Electronic address
    Cancer Treat Rev 40:675-83. 2014
    ..We conducted a systematic review and meta-analysis of randomized trials evaluating the efficacy of GnRHa, given before and during chemotherapy, in the prevention of POF in premenopausal cancer patients...
  16. ncbi [The AIOM (Italian Association of Medical Oncology) practice guidelines for breast neoplasms]
    Lucia Del Mastro
    Oncologia Medica A, Istituto Nazionale per la Ricerca sul Cancro, Genova
    Tumori 90:1-8. 2004
  17. doi Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies
    Matteo Lambertini
    Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy Department of Medicine, BrEAST Data Centre, Institut Jules Bordet and l Université Libre de Bruxelles U L B, Brussels, Belgium Electronic address
    Eur J Cancer 71:34-42. 2016
    ..We performed a pooled analysis of two randomised clinical trials to evaluate the efficacy of adjuvant dose-dense chemotherapy in premenopausal breast cancer patients and its impact on the risk of treatment-induced amenorrhoea...
  18. doi Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial
    Matteo Lambertini
    Department of Medical Oncology, U O Oncologia Medica A, IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    JAMA 314:2632-40. 2015
    ....
  19. ncbi Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer
    Alessia Levaggi
    Innovative Therapies Development Unit Department of Medical Oncology, IRCCS AOU San Martino IST National Institute for Cancer Research, Genoa, Italy
    Anticancer Res 34:3715-20. 2014
    ..The objectives of this study were to determine the incidence of positive serology for hepatitis B and C in women with early breast cancer and to assess the clinical course and its impact on liver function during adjuvant treatments...
  20. doi Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial
    Matteo Lambertini
    Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino IST, Largo Rosanna Benzi, 10, 16132, Genova, Italy
    Support Care Cancer 24:1285-94. 2016
    ....
  21. doi 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial
    Lucia Del Mastro
    Department of Medical Oncology, IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Largo R Benzi 10, 16132, Genoa, Italy
    Breast Cancer Res Treat 155:117-26. 2016
    ..Our study failed to demonstrate a superiority of an adjuvant treatment with four EP as compared to six FEC in node-positive breast cancer patients. ..
  22. ncbi Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
    Paolo Bruzzi
    Unit of Clinical Epidemiology, National Institute for Cancer Research, Largo Rosanna Benzi 10, 16132 Genoa, Italy
    J Clin Oncol 23:5117-25. 2005
    ..To assess the validity of objective response to chemotherapy as a surrogate end point for survival in metastatic breast cancer...
  23. ncbi Treatment with aromatase inhibitors and markers of cardiovascular disease
    Eva Blondeaux
    Department of Medical Oncology U O Oncologia Medica 2 IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Breast Cancer Res Treat 160:261-267. 2016
    ..We carried out a cross-sectional study to evaluate the effect of estrogen deprivation induced by aromatase inhibitors on markers of cardiovascular risk...
  24. pmc Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study
    Matteo Clavarezza
    E O Ospedali Galliera, Genoa, Italy
    Oncologist 18:924-5. 2013
    ..Adjuvant dose-dense (DD) chemotherapy is more effective than regimens administered every 3 weeks, especially in hormonal receptor (HR)-negative tumors...
  25. doi Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients
    Claudia Bighin
    Department of Medical Oncology, IRCCS Istituto di Ricovero and Cura a Carattere Scientifico AOU Azienda Ospedaliera Universitaria San Martino IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Future Oncol 9:955-7. 2013
    ..TDM-1 is superior and less toxic than lapatinib plus capecitabine in metastatic breast cancer patients previously treated with trastuzumab and taxanes, and its role as a first-line therapy is currently under investigation...
  26. ncbi Sentinel lymph node biopsy in breast cancer patients: the medical oncology perspective
    Tiziana Catzeddu
    Division of Medical Oncology, National Cancer Reasearch Institute, Genoa, Italy
    J Surg Oncol 85:129-32. 2004
    ..The new version of the staging system of breast cancer has recognised the need for a standard diagnostic approach and of a nomenclature system which also takes SLNB into account...
  27. doi Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients
    Francesca Poggio
    a Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino IST, Genova, Italy
    Expert Rev Clin Pharmacol 9:1153-61. 2016
    ..Fulvestrant is a selective estrogen receptor down-regulator (SERD) with demonstrated activity and efficacy in the treatment of these patients...
  28. doi News on the medical treatment of young women with early-stage HER2-negative breast cancer
    Matteo Lambertini
    a Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino, IST, Genova, Italy
    Expert Opin Pharmacother 17:1643-55. 2016
    ..Breast cancer in young women represents a public health problem with specific age-related issues to be faced by both patients and their treating physicians...
  29. pmc Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
    Silvia Boero
    Unit of Molecular Oncology and Angiogenesis, IRCCS AOU San Martino IST, Genoa, Italy
    J Transl Med 13:324. 2015
    ..This study was aimed to evaluate in vitro the functional relationships among FcγRIIIA/IIA polymorphisms, ADCC intensity and HER-2 expression on tumor target cells and to correlate them with response to trastuzumab...
  30. doi Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
    Lucia Del Mastro
    Department of Medical Oncology, IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy Electronic address
    Lancet 385:1863-72. 2015
    ..We aimed to address these questions in terms of improvements in disease-free survival...
  31. ncbi [Epoetin in cancer patients. Guidelines of the ASCO and the ASH for evidence-based clinical practice]
    Lucia Del Mastro
    Oncologia Medica A, Istituto Nazionale per la Ricerca su Cancro, Genova
    Tumori 89:1-12. 2003
  32. ncbi Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial
    Marco Venturini
    Institution of Oncologia Medica, Sperimentazioni Cliniche Controllate Istituto Nazionale per la Ricerca sul Cancro, Genova PB, Italy
    J Natl Cancer Inst 97:1724-33. 2005
    ....
  33. doi Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies
    Matteo Lambertini
    BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, and l Université Libre de Bruxelles U L B, Brussels, Belgium Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino IST, Genoa, Italy
    Cancer Treat Rev 49:65-76. 2016
    ..In this meta-analysis we evaluated the association between parity, age at first birth, breastfeeding and the risk of developing breast cancer according to tumor subtype...
  34. doi Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
    Matteo Lambertini
    Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy Department of Medicine, BrEAST Data Centre, Institut Jules Bordet and l Université Libre de Bruxelles U L B, Brussels, Belgium Electronic address
    Eur J Cancer 71:25-33. 2016
    ..The present manuscript aims to update and summarise the evidence for the use of this strategy in light of the new data published up to January 2016, according to the GRADE process...
  35. doi New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients
    Lucia Del Mastro
    UO Development of Innovative Therapies, IRCCS AOU San Martino IST, National Institute for Cancer Research, L go R Benzi 10, 16132 Genova, Italy Electronic address
    Cancer Treat Rev 42:18-23. 2016
    ....
  36. doi Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors
    Matteo Lambertini
    a Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino IST, 16132 Genoa, Italy
    Expert Opin Biol Ther 15:1799-817. 2015
    ....
  37. pmc Cancer and fertility preservation: international recommendations from an expert meeting
    Matteo Lambertini
    Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino IST, Genoa, Italy
    BMC Med 14:1. 2016
    ..The participation to the ongoing registries and prospective studies is crucial to acquire more robust information in order to provide evidence-based recommendations. ..
  38. pmc Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study
    Matteo Lambertini
    Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino IST, Genova, Italy Department of Medical Oncology, Hospital de Santa Maria and Instituto de Medicina Molecular of the Faculty of Medicine of the University of Lisbon, Lisbon, Portugal Department of Oncology, AOU S M Misericordia, University Hospital, Udine, Italy Medical Oncology, IRCCS Fondazione Maugeri, Pavia, Italy Investigative Clinical Oncology INCO, Fondazione del Piemonte per L Oncologia, Candiolo Cancer Center IRCCS, Candiolo, Italy Division of Medical Oncology, Ospedale Civile di Saluzzo, Saluzzo, Italy Department of Radiology, Oncology and Human Pathology, Oncology Unit B, Sapienza University of Rome, Rome, Italy Medical Oncology, Azienda Ospedaliera Universitaria di Sassari, Sassari, Italy Department of Medical Oncology, Clinica di Oncologia Medica, IRCCS AOU San Martino IST, Genova, Italy Oncology Unit, Sant Andrea Hospital, Sapienza University of Rome, Rome
    Oncologist 20:880-9. 2015
    ..We evaluated the patterns of care and clinical outcomes of metastatic breast cancer patients treated with first-line trastuzumab-based therapy after previous (neo)adjuvant trastuzumab...
  39. doi Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab
    Barbara Cardinali
    Development of Innovative Therapies Unit, IRCCS AOU San Martino IST, 16132, Genoa, Italy
    Anal Bioanal Chem 406:4557-61. 2014
    ..The procedure was also tested in sera obtained from breast cancer patients to evaluate trastuzumab serum levels, confirming the applicability of method that could be a valid assay to use in daily laboratory practice. ..
  40. pmc Fertility counseling of young breast cancer patients
    Matteo Lambertini
    S C Oncologia Medica A, IRCCS AOU San Martino IST, Genova, Italy
    J Thorac Dis 5:S68-80. 2013
    ....
  41. doi Exploring the safety of chemotherapy for treating breast cancer during pregnancy
    Matteo Lambertini
    a 1 Department of Medical Oncology, U O Oncologia Medica 2, IRCCS AOU San Martino IST, Genova, Italy
    Expert Opin Drug Saf 14:1395-408. 2015
    ..A proper understanding of the safety of chemotherapy during pregnancy is a vital step to avoid detrimental consequences on the mother and the fetus...
  42. doi Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients
    Claudia Bozza
    Department of Oncology, University Hospital of Udine, Udine, Italy Department of Medical and Biological Sciences, University of Udine, Udine, Italy Department of Medical Oncology UO Oncologia Medica A, IRCCS AOU San Martino IST, Largo Rosanna Benzi, 10, 16132 Genova, Italy Department of Radiation Oncology, New York University School of Medicine, New York, New York, USA Mother and Child Department, Pordenone Hospital, Pordenone, Italy Department of Medical Oncology SS Sviluppo Terapie Innovative, IRCCS AOU San Martino IST, Genova, Italy
    Endocr Relat Cancer 21:R51-65. 2014
    ..Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH. ..
  43. doi Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and beta2-microglobulin downregulation in breast cancer
    Anna Morabito
    Breast Cancer Laboratory of Tumour Genetics Unit, National Cancer Research Institute, Genoa, Italy
    Hum Immunol 70:492-5. 2009
    ..This result may correlate with the role of beta2-m in regulating cancer cell growth...
  44. doi Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
    Diana Crivellari
    IBCSG Coordinating Center, Effingerstrasse 40, CH 3008 Bern, Switzerland
    J Clin Oncol 26:1972-9. 2008
    ..To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial...
  45. ncbi Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
    Crit Rev Oncol Hematol 63:53-64. 2007
    ..A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer...
  46. ncbi Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
    Alan S Coates
    International Breast Cancer Study Group IBCSG, IBCSG Coordinating Center, Bern, Switzerland
    J Clin Oncol 25:486-92. 2007
    ..Because this presentation may unduly reflect early events, the present analysis is limited to patients randomly assigned to the continuous therapy arms and includes protocol-defined updated results...
  47. ncbi Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer
    Gianfilippo Bertelli
    South West Wales Cancer Institute, Swansea, United Kingdom
    Oncology 69:471-7. 2005
    ..If exemestane is used as first anti-aromatase agent, however, it is unclear whether patients can still benefit from letrozole or anastrozole after progression...
  48. ncbi Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer
    Gianfilippo Bertelli
    South West Wales Cancer Institute, University of Wales Swansea, Swansea, UK
    Oncology 68:364-70. 2005
    ..We investigated the effects of the third-generation aromatase inhibitor letrozole as a maintenance therapy in postmenopausal patients who had responded or had stable disease with first-line chemotherapy...
  49. ncbi ATAC trial update
    Lucia Del Mastro
    Lancet 365:1225; author reply 1225-6. 2005
  50. ncbi Weekly paclitaxel in elderly patients with advanced breast cancer: a dose-finding study
    Lazzaro Repetto
    Unità Operativa di Oncologia INRCA, Rome, Italy
    Drugs R D 5:11-5. 2004
  51. ncbi Fertility preservation strategies for breast cancer patients
    Lucia Del Mastro
    J Clin Oncol 24:4220-1; author reply 4221-2. 2006
  52. ncbi Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy
    Matteo Clavarezza
    J Natl Cancer Inst 99:1050-1; author reply 1051-2. 2007